-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-06-15
IVBIY:OTC-IVBIY (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 29Change
0.00 (0.00)%Market Cap
USD 16.84BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Values as of: 2025-06-15
COMMON STOCK | Biotechnology |
Last Closing
USD 29Change
0.00 (0.00)%Market Cap
USD 16.84BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Company Website : https://www.innoventbio.com
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
UCBJF | UCB SA |
N/A |
USD 37.40B |
ARGNF | argenx SE |
N/A |
USD 34.32B |
UCBJY | UCB SA ADR |
N/A |
USD 33.77B |
GNMSF | Genmab A/S |
N/A |
USD 14.10B |
WXIBF | WuXi Biologics |
N/A |
USD 12.07B |
WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 12.07B |
AKESF | Akeso, Inc. |
N/A |
USD 9.60B |
SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 9.28B |
SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 8.94B |
TLPPF | Telix Pharmaceuticals Limited |
N/A |
USD 5.59B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 51.44% | 79% | B- | 83% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 51.44% | 79% | B- | 83% | B | ||
Trailing 12 Months | |||||||
Capital Gain | 48.87% | 80% | B- | 82% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 48.87% | 80% | B- | 81% | B- | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 1.62% | 56% | F | 48% | F | ||
Dividend Return | 1.62% | 56% | F | 44% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 9.03% | 98% | N/A | 96% | N/A | ||
Risk Adjusted Return | 17.93% | 76% | C+ | 58% | F | ||
Market Capitalization | 16.84B | 99% | N/A | 93% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.